Back to today’s briefing

Story perspectives

CRISPR Therapeutics Soars 14% After Promising Therapy Insights

6/12/2025

48 7

Summary

Story summary

At the Goldman Sachs Healthcare Conference, CRISPR Therapeutics CEO Samarth Kulkarni passionately highlighted the promise of CAR-T therapies for autoimmune diseases and celebrated the success of CASGEVY, a groundbreaking gene therapy for sickle cell disease. Following encouraging data from CTX310, a new in vivo therapy, shares surged 14%, showcasing CRISPR's resilience amid competition and robust financial health.

1 of 1

Story summary

At the Goldman Sachs Healthcare Conference, CRISPR Therapeutics CEO Samarth Kulkarni passionately highlighted the promise of CAR-T therapies for autoimmune diseases and celebrated the success of CASGEVY, a groundbreaking gene therapy for sickle cell disease. Following encouraging data from CTX310, a new in vivo therapy, shares surged 14%, showcasing CRISPR's resilience amid competition and robust financial health.